Advertisement

Topics

Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use

07:55 EDT 23 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
If approved, IMRALDI would be the third anti-TNF biosimilar in Biogen’s portfolio in Europe, helping to expand affordable therapy options and increase access for patients with chronic anti-inflammatory disorders such as rheuma...

Other Sources for this Article

BIOGEN EU MEDIA CONTACT:
Benjamin Russell, +41 41 392 1922
publicaffairs.EU@biogen.com
or
BIOGEN INVESTOR CONTACT:
Mike Hencke, +1 781-464-2442
IR@biogen.com

NEXT ARTICLE

More From BioPortfolio on "Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...